Optimize: Mood & Stress

Foundational empower-first mood lever. Gordon 2018 meta (JAMA Psychiatry, PMID 29800984): resistance training meaningfully reduced depressive symptoms, roughly 1 in 4 responding, largely independent of how much strength was gained. Small-to-moderate on anxiety too. Belongs at the top with aerobic exercise.

Everyday movement is a first-line mood lever. 7,000+ steps/day tracked with ~31% lower rate of new depression (prospective, associational). Read together with the broader exercise-for-depression evidence (see completeness). Free, accessible, no equipment.

Reducing isolation and loneliness is foundational. Holt-Lunstad 2010/2015 (PMID 20668659, 25910392): strong social ties ~50% higher survival odds; isolation/loneliness/living-alone each 26-32% higher mortality. Association, not proven cause (the isolated differ in health, income, mobility) so name the confounders. Best intervention target is loneliness-driving thoughts (~0.6 SD), not just adding contact; talking therapy g~0.43; video calls alone did little.

Mindfulness gives small-to-moderate drops in anxiety (~0.38 SD) and depression (~0.30 SD) at 8 weeks, roughly level with CBT and medication and well above a waiting list. MBCT cuts depression relapse ~31% vs usual care. Self-directed and free; app-based works for stress. Little effect on positive mood/sleep/weight.

Eases depression more than usual care (SMD ~-0.69) and anxiety a small amount; in GAD, 54% improved vs 33% on stress education, below CBT (71%). Combines movement, breath and attention, which is part of why it ranks well.

Best-evidenced botanical here: ~30 mg/day beat placebo and matched standard antidepressants for mild-to-moderate depression, with an anxiety signal and a strong PMS effect. Caveat: most trials are small and single-region; see overGradedTiers on the antidepressant-equivalence claim.

Slow breathing near 6 breaths/min eases anxiety a small-to-moderate amount across 58 trials; HRV biofeedback gave a large drop in stress/anxiety (Hedges g ~0.83) and a smaller one in depression (g ~0.38). Free once learned; the practice is the lever, the HRV number is a marker.

Structured outdoor programs over 8-12 weeks lift mood most; ~120 min/week tracks better wellbeing. The green setting adds to mood but not to blood pressure or cortisol, and several sub-signals (blue space, forest bathing) are emerging with publication bias. Accessible and free.

Strongest as risk reduction: ~33% lower risk of developing depression at highest adherence. The diet-as-active-treatment claim rests on small trials (see overGradedTiers). A foundational background support rather than a fast mood fix.

Rising sense of purpose tracked with ~43% lower odds of becoming depressed and less loneliness across 135,227 people; structured programs raised wellbeing a moderate amount. Cultivable, empower-first.

Fewer depression symptoms across 64 RCTs and more positive everyday mood, but gains shrink to near zero against an engaging active comparator (d~0.11 anxiety, ~0.31 wellbeing vs nothing). Real, small, and easy to do; do not oversell versus other pleasant activities.

Strongest for seasonal/winter depression: morning bright light effect size ~0.84, in the antidepressant range (Golden 2005, PMID 15800134). Weaker/preliminary as a general daytime-light-and-mood association. Underrated for non-seasonal depression too (see completeness).

~24% lower depression risk in coffee drinkers, observational and confounded (drinkers differ in health and activity). A modest background association, not a treatment; do not present as causal.

Erratic sleep timing tracked most strongly with depression and stress across 53 studies; >2h social jetlag went with higher depression scores. Foundational in principle but the mood-specific evidence here is correlational. Improving sleep is a genuine mood lever (see completeness).

Only for non-anemic iron deficiency: iron eased anxiety and improved memory in that subgroup. Not a mood lever for iron-replete people, and iron carries real overload risk, so it is a correct-the-deficiency lever, not a general supplement.

NAC left 56% of adults with trichotillomania much improved vs 16% placebo (a specific body-focused-repetitive-behavior use); only a small effect on general depression. Situational rather than a broad mood lever.

Reduce-lever: over 25 years the evidence best fit alcohol problems causing depression, not the reverse. Cutting back is the actionable move; never framed as 'drink less to feel good tonight'.

Reduce-lever: hearing loss is linked to higher depression odds (35 studies, ~147,000 people) and to loneliness/isolation. Protecting and correcting hearing is an empower-first, addressable mood lever, especially with age.

A bipolar-safe CBT-I cut mania relapse from 31.6% to 4.6% by protecting sleep. Highly situational (bipolar sleep management); the general point, that treating insomnia helps mood, is real (see completeness).

Low B12/folate is associated with depression in older adults, but that is an association only. A correct-the-deficiency lever if levels are low, not a general mood supplement.

Last-resort, clinician-administered. A single IV infusion raised remission odds ~sevenfold at 24h and rapidly cut suicidal ideation, but the effect fades within a week without maintenance. Real and important for treatment-resistant depression; not a self-directed lever. Education-level framing. Note: overlaps with the esketamine claim under psychedelics.

Education-level hub. Psilocybin, MDMA-assisted therapy, ayahuasca and esketamine show real early signals for treatment-resistant depression, PTSD and end-of-life distress, but they are administered in clinical/legal trial settings with therapy, carry meaningful risk, and psilocybin did not clearly beat a standard antidepressant; microdosing matched placebo. Present as education, never as a self-directed empower-first lever. Individual medicine pages (psilocybin, mdma, ayahuasca, ibogaine) inherit this framing.

The implant did not beat sham acutely (~15% vs 10%) though a 5-year registry favored it (68% vs 41%, uncontrolled). Non-invasive ear-clip taVNS eased depression on par with citalopram in one 107-patient trial. A clinical device path, not empower-first; taVNS is the only self-adjacent form and it is early.

Cut perceived stress in two 60-day trials; pooled anxiety effect was large (SMD -1.55) but the trials disagreed sharply (I-squared 93.8%), so the true effect is uncertain. Short-term use; liver-safety signals belong in cautions.

Less burnout and stress-related fatigue than placebo over 28 days; depression signals were inconclusive against sertraline and placebo. Reasonable for stress/burnout, weak for diagnosed depression.

Lower felt stress ~1h after a dose and lower cortisol at 3h; a 4-week trial lowered depression and trait anxiety, but a 28-day stress trial found no difference. Mild, well-tolerated, acute-leaning.

Suggestive anxiety relief in anxiety-prone people on poor-quality evidence (18 studies). Cheap and safe; most useful where intake is low.

EPA-predominant fish oil modestly improved depressive symptoms; DHA-heavy products did not. The EPA/DHA ratio matters, which is why blanket 'fish oil for mood' claims mislead. Arguably under-ranked as an adjunct (see completeness).

Lowered depression scores across 6 small trials and matched fluoxetine in one 6-week study; bioavailability and small samples limit confidence.

Cortisol fell ~16% and testosterone rose ~37% over 4 weeks under stress in a small trial. Early, hormone-mediated; the mood endpoint is indirect.

A single 300 mg dose lowered anxiety before a public-speaking test, while 150 and 600 mg did not (a U-shaped dose response). Acute, situational, dose-fussy.

Structured pranayama cut stress and anxiety a large amount (SMD -1.25) across 7 small studies. Free and self-directed; evidence base thin but consistent.

Stress, anxiety and low mood fell a moderate-to-large amount on low-quality evidence; in the most rigorous trial the benefit shrank once compared with music or a waiting list. Pleasant, low-risk.

Lower depression, anxiety and stress across 35 student trials and moderately better quality of life across 19 trials; benefit fades once practice stops, so it is a keep-doing-it lever.

Seated tai chi lowered depression and raised quality of life in wheelchair users; gentle, accessible, thin evidence for mood specifically.

Lowered anxiety across 27 studies, strongest in hospital patients where expectation and touch both contribute. Self-applied and free.

One whole-body heat session lowered depression ~6.5 points at a week (still 4.3 down at six weeks); cold raises noradrenaline ~530% for same-day alertness. Heat has the clearer mood signal; see heat-exposure and sauna-alternatives.

A single deep-heating (hyperthermia) session lowered depression scores ~6.5 points at one week. Small trials; the antidepressant signal from whole-body heating is one of the more interesting emerging ones.

Twice-weekly hot baths lowered depression scores 4.3 points more than exercise at two weeks. A cheap at-home route to the heat effect.

Honest read: mood itself did not change after a cold plunge; only felt stress dropped, and only at 12 hours. The alertness lift is real (noradrenaline) but this is not a depression lever. Do not surface as a mood treatment.

Ten sessions added to medication lowered depression more than sham; open-label wellbeing gains lack controls. Expensive, adjunctive, early.

One double-blinded hour of real vs sham grounding improved mood more in 40 adults. Single small acute study; mechanism unclear.

In 710 young adults, worry-prone people who ate more fermented food reported fewer social-anxiety symptoms. Cross-sectional, gut-brain hypothesis, low-risk.

Better mood after four weeks in perimenopausal women in one small trial. Preliminary; not established for general mood.

Anxiety and depression eased over 12 months in an MS cohort. Confounded by an intensive whole-lifestyle change; not a stand-alone mood lever.